Bio-Rad Laboratories, Inc. (NYSE:BIO) Forecasted to Post Q1 2025 Earnings of $2.39 Per Share

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Equities research analysts at Zacks Research lifted their Q1 2025 earnings estimates for shares of Bio-Rad Laboratories in a research report issued to clients and investors on Monday, April 15th. Zacks Research analyst R. Anand now forecasts that the medical research company will earn $2.39 per share for the quarter, up from their previous forecast of $2.35. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.41 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q3 2025 earnings at $3.83 EPS.

Several other research firms also recently weighed in on BIO. UBS Group upped their price target on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. Royal Bank of Canada reduced their price target on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Finally, Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their price target for the stock from $400.00 to $365.00 in a report on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $468.00.

Bio-Rad Laboratories Stock Down 0.7 %

BIO opened at $290.78 on Wednesday. Bio-Rad Laboratories has a twelve month low of $261.59 and a twelve month high of $489.36. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14. The company has a 50-day moving average price of $331.66 and a 200 day moving average price of $321.00. The company has a market cap of $8.29 billion, a PE ratio of -13.53 and a beta of 0.87.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.17. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The firm had revenue of $681.18 million during the quarter, compared to the consensus estimate of $685.00 million. During the same quarter in the prior year, the firm earned $3.31 EPS. The company’s revenue for the quarter was down 6.7% on a year-over-year basis.

Institutional Investors Weigh In On Bio-Rad Laboratories

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Lecap Asset Management Ltd. purchased a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at about $1,590,000. Comerica Bank acquired a new stake in shares of Bio-Rad Laboratories in the third quarter valued at approximately $11,054,000. IFM Investors Pty Ltd grew its position in shares of Bio-Rad Laboratories by 5.2% in the third quarter. IFM Investors Pty Ltd now owns 4,057 shares of the medical research company’s stock valued at $1,454,000 after purchasing an additional 200 shares during the last quarter. Thompson Siegel & Walmsley LLC grew its position in shares of Bio-Rad Laboratories by 6.3% in the third quarter. Thompson Siegel & Walmsley LLC now owns 312,583 shares of the medical research company’s stock valued at $112,046,000 after purchasing an additional 18,419 shares during the last quarter. Finally, Caxton Associates LP acquired a new stake in shares of Bio-Rad Laboratories in the third quarter valued at approximately $668,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP Michael Crowley sold 3,000 shares of Bio-Rad Laboratories stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the completion of the sale, the executive vice president now directly owns 6,942 shares of the company’s stock, valued at approximately $2,332,512. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 17.50% of the stock is currently owned by corporate insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.